An Introduction to Psoriatic Arthritis
Psoriatic arthritis is a chronic, progressive, inflammatory form of arthritis, which develops in up to 30% of people with psoriasis and is associated with increased risk of systemic inflammatory disease. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, disease-modifying antirheumatic drugs (DMARDs) and biologic therapies, including inhibitors of tumour necrosis factor (TNF) α, interleukin (IL)-12, IL-23 and IL-17. Recently approved therapies include the Janus kinase (JAK) inhibitors, and other promising agents in development include tyrosine kinase inhibitors. Future challenges include personalised medicine, earlier diagnosis and achieving a low-level of disease activity.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Psoriatic Arthritis Content
Michaela Koehm, ACR 2021: Methotrexate Effect on bDMARDs in the Treatment of Active PsA
We were delighted to speak with Dr. Michaela Koehm (Goethe University, Frankfurt am Main, Germany) to discuss her trial investigating the effect of methotrexate on ustekinumab treatment for active psoriatic arthritis. The abstract ‘Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical […]
Atul Deodhar, ACR 2021: Efficacy of Deucravacitinib by Baseline DMARD Use in Psoriatic Arthritis
It was a pleasure to discuss with Prof. Atul Deodhar (Oregon Health & Science University, Portland, OR, USA) the results from the further exploratory analysis of the phase 2 trial (NCT03881059) investigating the TYK2 inhibitor, deucravacitinib, in patients with psoriatic arthritis treated with and without background conventional synthetic DMARDs. This information is brought to you […]
Merav Lidar, ACR 2021: Efficacy and Safety of Risankizumab in Psoriatic Arthritis
Prof. Merav Lidar (Sheba Medical Center, Tel Hashomer, Israel) kindly took the time to discuss the 24-week efficacy and safety results from the KEEPsaKE2 trial (NCT03671148). This phase 3 randomized, double-blind trial investigated the humanized immunoglobulin G1 monoclonal antibody, risankizumab, in adults with psoriatic arthritis (PsA). This information is brought to you by Touch Medical […]
Ana-Maria Orbai, ACR 2021: Effect of Guselkumab on General Health Outcomes using the PROMIS-29
touchIMMUNOLOGY had the pleasure of discussing with Dr Ana-Maria Orbai (Johns Hopkins University School of Medicine, Baltimore, MD, USA) the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) instrument and its use in assessing the effect of guselkumab on general health outcomes in patients with psoriatic arthritis in the DISCOVER-1 trial (NCT03162796). This information is brought to […]
Laure Gossec, ACR 2021: Long-term Impact of Bimekizumab on Patient-reported Outcomes in PsA
Prof. Laure Gossec (Sorbonne Universite, Paris, France) kindly took the time to speak with touchIMMUNOLOGY about the long-term impact of the IgG1 inhibitor, bimekizumab, on patient-reported outcomes from the phase 2b BE ACTIVE study (NCT02969525) and its open-label extension (NCT03347110). This information is brought to you by Touch Medical Media and is not sponsored by, […]
Laure Gossec, ACR 2021: Treatment Persistence with Ustekinumab or TNF Inhibitors in PsA
It was a pleasure to speak with Prof. Laure Gossec (Sorbonne Universite, Paris, France) about the recent real-world data surrounding the long-term persistence of ustekinumab and TNF inhibitors in patients with PsA (NCT02627768). This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College […]
Denis Poddubnyy, ACR 2021: Efficacy of Ixekizumab in Psoriatic Arthritis with Symptoms of Axial Involvement
It was a pleasure to discuss with Prof. Denis Poddubnyy (Charité-Universitätsmedizin Berlin, Berlin, Germany) the post-hoc analysis from sub-populations of the phase 3 SPIRIT-1 (NCT01695239) and SPIRIT-2 (NCT02349295) trials aimed at determining the efficacy of ixekizumab in reducing axial symptoms and improving quality of life in patients with PsA and symptoms of axial involvement. This […]
Maarten Boers, EULAR 2021: Findings from the ULTIMATE Clinical Trial
It was great to talk with Prof. Maarten Boers (VU University Medical Center, Amsterdam, The Netherlands) to discuss the responsiveness and high discriminative validity of GLOESS and clinical outcomes of synovitis in PsA patients treated with secukinumab from the ULTIMATE Trial. The abstract ‘Responsiveness of Ultrasound Synovitis and Clinical Outcomes in Psoriatic Arthritis Treated with […]
Xenofon Baraliakos, EULAR 2021: Findings from the MAXIMISE Study
It was a pleasure to meet with Prof. Xenofon Baraliakos (Ruhr-University Bochum, Herne, Germany) to talk around his presentation on ‘Secukinumab in patients with psoriatic arthritis and axial manifestations: Predictors of response from the double-blind, randomised, phase 3b MAXIMISE trial.‘ (POS0930), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!